Mannosyltransferase 2 Deficiency

Mannosyltransferase 2 deficiency is a very rare, inherited condition. It happens when both copies of a gene called ALG2 do not work well. The ALG2 gene makes an enzyme that adds the sugar mannose to a growing sugar chain inside the endoplasmic reticulum of our cells. This step is part of N-linked glycosylation, a process that helps proteins fold, travel, and work properly. When ALG2 is not working, many proteins in many organs are not glycosylated correctly. This can affect the brain, eyes, muscles, nerves, liver, blood clotting system, growth, and development. The condition is autosomal recessive (a child is affected when they inherit one non-working copy from each parent). rarediseases.info.nih.gov+3NCBI+3Wikipedia+3

Inside the endoplasmic reticulum, cells build a special “sugar tree” on a lipid carrier (dolichol). ALG2 adds the second and third mannose units onto this sugar tree. If ALG2 is faulty, the sugar tree is too short. Many proteins then get under-glycosylated. These proteins do not fold correctly, do not move to the right place, or are removed early. Because glycoproteins are important in the brain, eyes, muscles, liver, immune and clotting systems, the disease looks multi-system. marrvel.org+2UCSC Genome Browser+2

Mannosyltransferase 2 deficiency is a rare genetic disease that affects the way the body builds sugar chains on proteins. These sugar chains are called glycans. They are added to many proteins in a process called N-linked glycosylation. In this condition, a gene named ALG2 does not work properly. The ALG2 gene gives the instructions for an enzyme (a tiny machine) called alpha-1,3/1,6-mannosyltransferase. This enzyme’s job is to attach the second and third mannose sugars to a growing sugar chain on a carrier molecule called dolichol inside the endoplasmic reticulum of the cell. If ALG2 is faulty, the sugar chain is not built correctly. As a result, many proteins in the body do not get the right glycans, so they do not fold or function well. Because many organs rely on these proteins, several body systems can be affected at the same time. The condition is inherited in an autosomal recessive way (a child must receive a non-working copy of ALG2 from both parents). Frontiers+2cdghub.com+2

---

Other names

• ALG2-CDG (preferred modern name)

• Alpha-1,3-mannosyltransferase 2 congenital disorder of glycosylation

• CDG-Ii (older name in the “Type I/Type II” system)

• ALG2-congenital disorder of glycosylation; OMIM 607906
  These names all refer to the same disorder caused by pathogenic (harmful) variants in the ALG2 gene. Frontiers+2cdghub.com+2

---

Types

Doctors describe ALG2-CDG in two helpful ways:

1. By pathway class
   ALG2-CDG belongs to the old “Type I” CDG group. Type I disorders affect building the lipid-linked oligosaccharide (the sugar chain on dolichol) before it is transferred to proteins. That is exactly where ALG2 works. In newer naming, we simply say ALG2-CDG instead of “CDG-Ii.” Wikipedia

2. By clinical pattern (severity and age at onset)
   There is a spectrum. Some babies have severe, early-onset disease with multi-organ involvement. Others have a moderate course with developmental delay, low muscle tone, and visual problems. Very mild cases are uncommon but possible, because the exact ALG2 variant and residual enzyme activity can change how the illness looks. (This variability has been described across published case series and reports.) PMC+1

---

Causes and contributors

In a single-gene condition, the primary cause is biallelic (both-copy) disease-causing variants in the gene. But many contributors/modifiers can shape how the disease appears. Below are 20 plain-language “causes and contributors” that together explain why ALG2-CDG happens and why it varies:

1. Biallelic pathogenic ALG2 variants. A child inherits one faulty copy from each parent. This is the root cause. Frontiers

2. Missense variants. A single letter change that alters one amino acid in ALG2 and reduces enzyme function. Missense changes are common in ALG2-CDG reports. preventiongenetics.com

3. Small deletions or in-frame changes. Less common but reported, these remove or add a few DNA bases and disrupt ALG2. preventiongenetics.com

4. Loss of ALG2 enzyme activity. The faulty protein cannot efficiently add the second/third mannose to the dolichol-linked chain. ScienceDirect

5. Failed completion of the lipid-linked oligosaccharide (LLO). The sugar chain is incomplete, so later steps cannot proceed normally. cdghub.com

6. Reduced transfer of glycans to proteins. Incomplete LLO means fewer or abnormal glycans on many proteins. Wikipedia

7. Protein misfolding and ER stress. Poor glycosylation can make proteins unstable, triggering cell stress responses that harm tissues. (General CDG mechanism.) NCBI

8. Abnormal clotting factor glycosylation. This can disturb blood coagulation and cause bleeding or clotting problems. rarediseases.info.nih.gov+1

9. Neurodevelopmental impact. Many brain proteins need correct glycosylation; disruption contributes to seizures, delayed milestones, and low tone. (CDG general mechanism, observed in ALG2-CDG.) NCBI+1

10. Eye development disruption. Ocular structures depend on properly glycosylated proteins; iris coloboma and cataracts have been reported in ALG2-CDG. rarediseases.info.nih.gov+1

11. Autosomal recessive inheritance pattern. Consanguinity increases the chance both parents carry the same variant. rarediseases.info.nih.gov

12. Compound heterozygosity. Two different damaging variants (one on each copy) can combine to cause disease. preventiongenetics.com

13. Residual enzyme activity differences. Some variants leave more activity than others, which changes severity. (Inferred from case variability.) PubMed

14. Modifier genes. Other glycosylation genes or quality-control pathways may influence how severe the disease becomes. (General CDG principle.) NCBI

15. Illness or metabolic stress. Fever, infections, or fasting can stress glycoprotein pathways and transiently worsen symptoms. (General observation across CDGs.) NCBI

16. Nutritional status. While ALG2-CDG is genetic, poor nutrition may aggravate growth or energy problems already present. (Supportive principle in CDGs.) NCBI

17. Liver involvement. Hypoglycosylation can impair liver-made proteins (e.g., clotting factors), amplifying systemic issues. NCBI

18. Developmental timing. Early brain and eye development are sensitive to glycosylation defects, shaping early-onset features. rarediseases.info.nih.gov

19. Population-specific variants. Some variants may cluster in certain regions or families. (General in rare autosomal recessive diseases.) preventiongenetics.com

20. Diagnostic delay. Because it is rare, late diagnosis can allow complications to accumulate before supportive care starts. (General for rare CDGs.) NCBI

---

Common symptoms and signs

1. Developmental delay. Children learn motor or language skills more slowly because many brain proteins are under-glycosylated. rarediseases.info.nih.gov+1

2. Low muscle tone (hypotonia). Poor glycosylation affects nerves and muscles, causing a “floppy” feel in infants. NCBI

3. Seizures or infantile spasms. Abnormal brain signaling may occur; infantile spasms are described in ALG2-CDG. rarediseases.info.nih.gov

4. Visual problems. Iris coloboma (a keyhole-shaped pupil) and cataracts have been reported. rarediseases.info.nih.gov+1

5. Feeding difficulties. Poor coordination or fatigue can make feeding slow or hard. NCBI

6. Poor growth/failure to thrive. Energy use is inefficient and illness is frequent, so weight and height can lag. NCBI

7. Abnormal blood clotting. Easy bruising, bleeding, or sometimes clots due to poorly glycosylated clotting factors. rarediseases.info.nih.gov

8. Liver involvement. Enlarged liver or abnormal liver enzymes may appear because the liver makes many glycoproteins. NCBI

9. Hearing issues. Sensorineural hearing loss is seen across several CDGs and may occur in ALG2-CDG. NCBI

10. Recurrent infections. Weakness, feeding issues, or impaired glycoproteins in immunity can add risk. NCBI

11. Distinctive facial features. Some children may have subtle dysmorphic features common in CDGs. NCBI

12. Movement or coordination problems. Ataxia or poor coordination can follow from cerebellar or peripheral nerve involvement. NCBI

13. Fatigability and weakness. Muscles tire easily because glycoprotein-dependent pathways are inefficient. (Noted broadly and in ALG2 resources.) GeneCards

14. Learning difficulties. Cognitive impairment can range from mild to severe. NCBI

15. Eye movement problems. Strabismus or nystagmus may be observed due to neurologic and ocular involvement. NCBI

Note: Not every child will have all of these. Severity varies widely. PMC

---

Diagnostic tests

Doctors combine clinical examination, specialist assessments, and laboratory/genetic testing. Below are 20 commonly used tests, grouped by type, each with a short explanation.

A) Physical examination (bedside observations)

1. General pediatric exam with growth charting. Checks weight, length/height, and head size over time; looks for failure to thrive or microcephaly. NCBI

2. Neurologic exam for tone and reflexes. Assesses hypotonia, reflexes, coordination, and signs of peripheral or central involvement. NCBI

3. Ophthalmologic inspection. Identifies visible iris coloboma, cataracts, and eye movement issues. rarediseases.info.nih.gov

4. Skin and chest/abdomen exam. Looks for bruising (bleeding tendency), hepatomegaly (enlarged liver), or other organ signs. NCBI

5. Developmental assessment. Uses milestone checklists to document delays in motor, language, and social skills. NCBI

B) Manual/bedside functional tests (simple, clinic-based checks)

6. Pull-to-sit test. Gauges head lag and axial tone in infants with hypotonia. NCBI

7. Postural reactions (e.g., sitting balance). Screens for truncal tone and coordination as the child sits or stands with support. NCBI

8. Feeding and swallow observation. Clinician watches feeding to assess coordination, fatigue, and aspiration risk. NCBI

9. Ocular motility examination. Follows targets to check pursuit, saccades, strabismus, and nystagmus. NCBI

10. Bedside coagulation risk review. Manual inspection for bruises, nosebleeds, or prolonged bleeding after minor injuries, prompting lab testing. rarediseases.info.nih.gov

C) Laboratory and pathological tests

11. Transferrin glycosylation testing by isoelectric focusing or mass spectrometry. This screening shows a Type I pattern in many defects that affect LLO assembly, including ALG2-CDG. Wikipedia

12. Serum N-glycan profiling (MS-based). Defines glycan abnormalities and supports a CDG diagnosis. PubMed

13. Genetic testing of the ALG2 gene (sequencing ± deletion/duplication). Confirms the diagnosis by finding biallelic pathogenic variants. preventiongenetics.com

14. Coagulation studies (PT/INR, aPTT, fibrinogen, specific factor levels). Detects abnormal clotting factor function. rarediseases.info.nih.gov

15. Liver function tests (AST/ALT, GGT, albumin). Looks for liver involvement common across CDGs. NCBI

16. Creatine kinase (CK) and basic metabolic panel. Screens for muscle involvement and metabolic stressors; nonspecific but useful in the work-up. NCBI

17. (Specialized) LLO analysis in fibroblasts. Research-level or specialty lab testing can show incomplete dolichol-linked oligosaccharides characteristic of ALG2 defects. ScienceDirect

D) Electrodiagnostic tests

18. Electroencephalogram (EEG). Evaluates seizures or infantile spasms and helps guide treatment. rarediseases.info.nih.gov

19. Nerve conduction studies/electromyography (as indicated). If weakness or neuropathy is suspected, these studies can assess peripheral nerve and muscle function. (Used variably across CDGs.) NCBI

E) Imaging tests

20. Brain MRI (and eye imaging as indicated). Brain MRI can reveal structural or myelination changes seen in several CDGs; ophthalmic imaging (e.g., slit-lamp, OCT) documents cataracts or structural eye anomalies. Findings guide care but are variable in ALG2-CDG. NCBI+1

Treatment overview

There is no approved disease-modifying therapy for ALG2-CDG today. Care is supportive and tailored to each patient’s symptoms (seizures, feeding, eyes, clotting, tone, development). Some CDG subtypes have nutrient “bypass” therapies (for example, mannose for MPI-CDG, galactose for PGM1-CDG, fucose for SLC35C1-CDG, manganese for TMEM165-CDG), but not ALG2. Research into new approaches is ongoing, yet still experimental. NCBI+1

Non-pharmacological treatments

1. Individualized care plan • Aligns neurology, ophthalmology, genetics, physio, nutrition, and social work • Coordination reduces missed issues and improves safety in a multi-system disease. NCBI

2. Physiotherapy • Builds strength, posture, and balance • Repeated, targeted practice promotes motor learning and prevents contractures in hypotonia. NCBI

3. Occupational therapy • Trains fine-motor skills and daily activities • Task-specific training improves independence and caregiver ease. NCBI

4. Speech-language therapy • Helps speech and swallowing • Oral-motor exercises and safe-swallow techniques lower aspiration risk. NCBI

5. Feeding therapy & texture modification • Safer, easier eating • Thickened liquids, pacing, and positioning reduce choking and improve intake. NCBI

6. Nutrition plans with high-calorie options • Supports growth • Calorie-dense foods and scheduled meals offset high energy needs. NCBI

7. Reflux management without medicines • Reduces vomit/aspiration • Upright positioning, smaller frequent feeds, and sleep head-elevation help. NCBI

8. Seizure safety education • Lowers injury risk • Rescue plans, supervision during bathing, and trigger logs improve home safety. NCBI

9. Low-vision services • Maximizes remaining sight • Lighting, contrast, and visual aids help daily function in cataract/coloboma. Orpha

10. Early intervention / special education • Boosts development • Structured play-based learning grows language and cognition. NCBI

11. Respiratory physiotherapy • Clears secretions • Chest physiotherapy and cough assistance reduce pneumonia risk. NCBI

12. Orthotics and adaptive seating • Improves stability • Ankle-foot orthoses and seating systems enhance posture and mobility. NCBI

13. Behavioral sleep strategies • Better sleep • Consistent routines and stimulus control improve sleep quality when seizures or reflux disrupt nights. NCBI

14. Dental care with aspiration precautions • Protects teeth and lungs • Positioning and suctioning lower aspiration during dental work. NCBI

15. Vaccinations on schedule • Prevents infections that worsen weakness and seizures • Standard immunizations including influenza and pneumococcal protect fragile patients. NCBI

16. Genetic counseling for family • Informs risks and options • Explains autosomal recessive inheritance and testing for relatives. NCBI

17. Social support & respite care • Reduces caregiver burnout • Practical help improves adherence to therapies. NCBI

18. Avoiding sedating environments and overheating • Limits fatigue and aspiration risk • External stressors can worsen hypotonia and myasthenic-like weakness. Frontiers

19. Physical fall-prevention home changes • Prevents injury • Rails, non-slip mats, and safe footwear matter in hypotonia/ataxia. NCBI

20. Emergency care plan (wallet card) • Faster, safer ER care • Lists diagnosis, seizure meds, and clotting issues for quick decisions. NCBI

Drug treatments

Always follow a specialist’s prescription. Doses and schedules are individualized. The medicines below are commonly used for symptoms seen in ALG2-CDG; none correct the glycosylation defect itself.

Seizures / infantile spasms

1. Levetiracetam (antiepileptic) • Purpose: broad-spectrum seizure control; often well-tolerated • Mechanism: modulates synaptic vesicle protein SV2A • Side effects: irritability, somnolence. NCBI

2. Valproate (antiepileptic) • Purpose: generalized seizures • Mechanism: increases GABA, modulates sodium/calcium channels • Side effects: weight gain, tremor, liver toxicity—use with caution if liver involvement. NCBI

3. Vigabatrin (antiepileptic) • Purpose: infantile spasms associated with certain etiologies • Mechanism: irreversible GABA-transaminase inhibitor • Side effects: visual field loss risk—requires eye monitoring. NCBI

4. Clobazam (benzodiazepine adjunct) • Purpose: add-on for refractory seizures • Mechanism: GABA-A positive modulation • Side effects: sedation, tolerance. NCBI

5. ACTH (adrenocorticotropic hormone) for infantile spasms • Purpose: spasm suppression • Mechanism: steroidogenic and neuro-anti-inflammatory effects • Side effects: hypertension, infection risk; specialist use only. NCBI

Neuromuscular (myasthenic-like) features in select cases

1. Pyridostigmine (acetylcholinesterase inhibitor) • Purpose: improves neuromuscular transmission • Mechanism: increases acetylcholine at the neuromuscular junction • Side effects: abdominal cramps, diarrhea; may not help all patients. Frontiers
2. Albuterol/salbutamol (beta-agonist) • Purpose: sometimes used in congenital myasthenic syndromes • Mechanism: enhances neuromuscular transmission via cAMP pathways • Side effects: tremor, tachycardia; specialist guided. Frontiers

Feeding/reflux / GI comfort

1. Proton-pump inhibitor (e.g., omeprazole) • Purpose: reflux control • Mechanism: blocks gastric acid pump • Side effects: diarrhea, headache. NCBI
2. Prokinetic (e.g., erythromycin low-dose) • Purpose: improves gastric emptying in severe reflux/aspiration risk • Mechanism: motilin receptor agonism • Side effects: cramps, QT risk with interactions. NCBI
3. Osmotic laxative (e.g., polyethylene glycol) • Purpose: constipation relief • Mechanism: draws water into stool • Side effects: bloating. NCBI

Tone/spasticity and sleep

1. Baclofen (antispasticity) • Purpose: reduces spasticity if present • Mechanism: GABA-B agonist in spinal cord • Side effects: sedation, hypotonia. NCBI
2. Melatonin • Purpose: sleep initiation • Mechanism: circadian signaling • Side effects: morning drowsiness. NCBI

Coagulation / bleeding-thrombosis balance

1. Vitamin K (if prolonged PT due to deficiency) • Purpose: supports clotting factors • Mechanism: cofactor for gamma-carboxylation • Side effects: rare allergy. rarediseases.info.nih.gov
2. Factor concentrates / FFP (per hematology) • Purpose: treats bleeding when specific factors are low • Mechanism: replaces missing proteins • Side effects: transfusion reactions; specialist protocols. rarediseases.info.nih.gov
3. Anticoagulation (e.g., low-molecular-weight heparin) in rare pro-thrombotic settings • Purpose: treat or prevent clots when indicated • Mechanism: anti-Xa activity • Side effects: bleeding; hematology oversight needed. NCBI

Infection prevention / treatment

1. Standard antibiotics when bacterial infections occur • Purpose: treat infections quickly • Mechanism: pathogen-specific • Side effects: drug-specific; follow culture and local guidelines. NCBI
2. Seasonal antivirals (e.g., oseltamivir for influenza when indicated) • Purpose: reduces severity/duration • Mechanism: neuraminidase inhibition • Side effects: nausea. NCBI

Ocular management

1. Topical ocular meds (lubricants, antibiotics post-op) • Purpose: protect cornea, prevent infection around eye surgery • Mechanism: moisture barrier/antimicrobial • Side effects: local irritation. Orpha

Bone health & general

1. Vitamin D • Purpose: bone strength, immunity support • Mechanism: calcium/phosphate regulation • Side effects: hypercalcemia if overdosed. NCBI
2. Analgesics (acetaminophen/ibuprofen) • Purpose: pain or fever control • Mechanism: central COX inhibition/antipyresis • Side effects: liver toxicity with acetaminophen overdose; ibuprofen gastric/renal cautions. NCBI

Note on dosages: dosing ranges are age- and weight-specific and must be set by clinicians; liver function and interactions matter in CDG care. NCBI

Dietary molecular supplements

None of these cures ALG2-CDG. They are supportive and should be used under medical guidance.

1. High-calorie formulas / powders • Function: weight gain • Mechanism: more calories per ml overcome feeding fatigue. NCBI

2. Medium-chain triglyceride (MCT) oil • Function: easy calories • Mechanism: fast absorption, less pancreatic demand. NCBI

3. Multivitamin with minerals • Function: fills gaps • Mechanism: broad micronutrient coverage. NCBI

4. Vitamin D • Function: bone & immune support • Mechanism: calcium balance and immune modulation. NCBI

5. Calcium (if diet is low) • Function: bone mineral support • Mechanism: mineral supply. NCBI

6. Omega-3 fatty acids • Function: anti-inflammatory, neuro support • Mechanism: membrane fluidity and eicosanoid shift. NCBI

7. Fiber supplements • Function: constipation relief • Mechanism: stool bulk and water retention. NCBI

8. Probiotics (selected strains) • Function: gut comfort • Mechanism: microbiome modulation (evidence variable; avoid in severe immunodeficiency). NCBI

9. Oral rehydration salts (during illness) • Function: prevent dehydration • Mechanism: glucose-sodium co-transport. NCBI

10. Iron (if iron-deficiency anemia) • Function: improve energy and development • Mechanism: hemoglobin synthesis. NCBI

Not recommended as disease-specific therapy: D-mannose has no proven benefit in ALG2-CDG (unlike MPI-CDG). NCBI

Regenerative / stem-cell drugs

1. There are no approved “immunity booster” or regenerative drugs for ALG2-CDG. Supportive care and vaccines are the evidence-based path. NCBI

2. Hematopoietic stem-cell transplant (HSCT) is not a standard treatment for ALG2-CDG because the defect is present in all tissues, not only blood cells. NCBI

3. Gene therapy (AAV or mRNA) is theoretical for ALG2; no clinical product exists yet. Researchers are exploring pathway-bypass strategies in CDG broadly, but these are experimental. ScienceDirect+1

4. Small-molecule chaperones or enzyme stabilizers might help misfolded enzymes in theory, but none are proven for ALG2. ScienceDirect

5. Lipid-linked sugar donors (e.g., liposomal M1P) are being studied for other CDG forms; they are not established for ALG2. ScienceDirect

6. Immunoglobulin (IVIG) is only for clear immune defects (not routine). Decision is specialist-driven. NCBI

Surgeries

1. Cataract extraction • Why: to improve vision and prevent deprivation amblyopia when cataracts impair sight. Orpha

2. Strabismus surgery • Why: aligns eyes to improve binocular vision and reduce diplopia. Orpha

3. Gastrostomy tube (G-tube) • Why: severe feeding problems or aspiration; ensures safe nutrition and meds. NCBI

4. Orthopedic procedures (tendon lengthening, scoliosis correction) • Why: comfort, function, and hygiene when contractures or curves are severe. NCBI

5. Hernia repair • Why: symptomatic umbilical/inguinal hernias sometimes occur and need fixing. NCBI

Prevention strategies

1. Stay on vaccination schedule (flu, pneumococcal, RSV plans if eligible). NCBI

2. Early seizure treatment plan to prevent status epilepticus. NCBI

3. Aspiration prevention (swallow plan, upright feeding). NCBI

4. Reflux control to lower pneumonia risk. NCBI

5. Nutrition support to prevent malnutrition. NCBI

6. Hematology guidance before surgeries/dental work (clotting plan). rarediseases.info.nih.gov

7. Fall-prevention at home (rails, non-slip) to reduce injuries. NCBI

8. Sick-day rules (hydration, earlier medical review) to handle infections fast. NCBI

9. Regular eye checks to protect vision. Orpha

10. Genetic counseling for family planning and carrier testing. NCBI

When to see doctors (red flags)

• Any new seizure, change in seizure pattern, or prolonged seizure. NCBI

• Feeding refusal, choking, or weight loss despite efforts. NCBI

• Signs of bleeding or clots (easy bruising, nosebleeds, limb swelling, chest pain). rarediseases.info.nih.gov

• Breathing problems, recurrent chest infections, or fever not settling. NCBI

• Eye concerns (white pupil/“cat’s eye” reflex, sudden vision change). Orpha

• Any sudden weakness or rapid fatigue suggesting myasthenic-like worsening. Frontiers

What to eat” and “what to avoid

Eat / emphasize

1. Energy-dense meals and snacks (nut butters, oils, dairy if tolerated) to support growth. NCBI

2. Adequate protein for muscle maintenance. NCBI

3. Soft/texture-modified foods if swallowing is hard. NCBI

4. Hydration, especially during illness. NCBI

5. Micronutrient-rich foods (eggs, leafy greens, legumes, fortified cereals). NCBI

Avoid / limit

1. Hard, dry, or crumbly foods if there is aspiration risk (nuts, chips). NCBI
2. Large single meals that worsen reflux; prefer small, frequent feeds. NCBI
3. Unsupervised “immune boosters” or megadose supplements (no proof, may harm clotting or liver). NCBI
4. Alcohol (teens/adults) and liver-toxic substances if liver tests are abnormal. NCBI
5. Long fasting times during illness; take early fluids and call your team. NCBI

FAQs

1) Is there a cure?
No. Supportive care targets symptoms. Research is active but experimental. ScienceDirect

2) How rare is it?
Very rare; only a small number of patients have been reported worldwide so far. Counts differ by source as new cases appear. cdghub.com+1

3) How is it inherited?
Autosomal recessive. Parents are usually healthy carriers. Each pregnancy has a 25% chance to be affected. rarediseases.info.nih.gov

4) How do doctors confirm it?
Transferrin glycosylation testing followed by genetic testing of ALG2. NCBI+1

5) Does D-mannose help?
No evidence it helps ALG2-CDG (it helps a different CDG subtype). NCBI

6) Will my child walk or talk?
Development varies. Early therapies improve skills, but outcomes are different for each child. NCBI

7) Are seizures common?
Seizures, including infantile spasms in some, are reported. Control often needs anti-seizure medicines. Orpha

8) Why are eyes affected?
Glycosylation is vital for eye development; reports include coloboma and cataract. Orpha

9) Can it look like a muscle junction problem?
Rarely, it can mimic congenital myasthenic syndrome with fatigable weakness. Frontiers

10) What specialists do we need?
Neurology, ophthalmology, genetics, physiatry/therapy, nutrition, hematology, gastroenterology. NCBI

11) Is surgery ever needed?
Sometimes—most often cataract or strabismus surgery, or G-tube for nutrition. Orpha

12) Can adults have ALG2-CDG?
Some individuals may survive into later childhood/adolescence; long-term data are limited because cases are so rare. cdghub.com

13) Are clinical trials available?
Trials in other CDG subtypes exist; ALG2-specific trials are not established yet. Ask your genetics team to check registries periodically. ScienceDirect

14) What can families do every day that helps most?
Keep therapies regular, follow feeding and seizure plans, keep vaccines current, and attend routine eye and lab checks. NCBI

15) Where can we learn more?
Rare-disease summaries (NIH/Orphanet/CDG Hub) and genetic counseling clinics are reliable sources. rarediseases.info.nih.gov+2Orpha+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.